Evidence map›Paper›PMID 23400275›Full record

ReviewArchivum immunologiae et therapiae experimentalis2013

Immune exhaustion and immune senescence: two distinct pathways for HBV vaccine failure during HCV and/or HIV infection.

Zhi Q Yao, Jonathan P Moorman

Abstract readReview
In one paragraph

Review in Archivum immunologiae et therapiae experimentalis, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed.

  1. Efficacy and Safety of a 3-Antigen (Pre-S1/Pre-S2/S) Hepatitis B Vaccine: Results of a Phase 3 Randomized Clinical Trial in the Russian Federation.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021
    Trial
  2. Trial
  3. Trial
  4. Observational
  5. Article
  6. Review
  7. Article
  8. Article
  9. Observational
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Zhi Q YaoDepartment of Veterans Affairs, Hepatitis (HCV/HBV/HIV) Program, James H. Quillen VA Medical Center, Johnson City, TN 37614, USA. yao@etsu.edu
Jonathan P Moorman

Funding

Tim-3-mediated IL-12 dysregulation in antiviral responses to HCV infectionR01DK093526 · NIDDK · EAST TENNESSEE STATE UNIVERSITY · PI YAO, ZHI Q. · 2012 to 2015
$1.2M
NIDDK NIH HHS R01 DK093526NIDDK NIH HHS R01DK093526
6 · The paper itself

Abstract

Given the shared risk factors for transmission, co-infection of hepatitis B virus (HBV) with hepatitis C virus (HCV) and/or human immunodeficiency virus (HIV) is quite common, and may lead to increases in morbidity and mortality. As such, HBV vaccine is recommended as the primary means to prevent HBV super-infection in HCV- and/or HIV-infected individuals. However, vaccine response (sero-conversion with a hepatitis B surface antibody titer >10 IU/L) in this setting is often blunted, with poor response rates to standard HBV vaccinations in virally infected individuals when compared with the healthy subjects. This phenomenon also occurs to other vaccines in adults, such as pneumococcal and influenza vaccines, in other immunocompromised hosts who are really at risk for opportunistic infections, such as individuals with hemodialysis, transplant, and malignancy. In this review, we summarize the underlying mechanisms involving vaccine failure in these conditions, focusing on immune exhaustion and immune senescence--two distinct signaling pathways regulating cell function and fate. We raise the possibility that blocking these negative signaling pathways might improve success rates of immunizations in the setting of chronic viral infection.

Indexed as

CoinfectionImmunocompromised HostSuperinfectionHepatitis B AntibodiesHepatitis B, ChronicHepatitis B Surface AntigensHepatitis B VaccinesHepatitis C, ChronicHIV InfectionsHumansRisk FactorsTreatment FailureHepatitis B AntibodiesHepatitis B Surface AntigensHepatitis B Vaccines

Identifiers

PMID23400275
PMCPMC3792483

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.